Eb-101    (DrugBank: -)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
36表皮水疱症3

36. 表皮水疱症 [臨床試験数:147,薬物数:170(DrugBank:40),標的遺伝子数:32,標的パスウェイ数:113
Searched query = "Epidermolysis bullosa", "EBS", "JEB", "DDEB", "RDEB", "Kindler syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 147 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04227106
(ClinicalTrials.gov)
January 10, 202010/1/2020Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)VIITAL: A Phase 3 Study of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)Epidermolysis Bullosa;Recessive Dystrophic Epidermolysis BullosaBiological: EB-101Abeona Therapeutics, IncNULLRecruiting6 YearsN/AAll15Phase 3United States
2NCT03632265
(ClinicalTrials.gov)
October 1, 201817/7/2018Study of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis BullosaVITAL: A Pivotal Phase 3 Study of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) (GENE TRANSFER)Recessive Dystrophic Epidermolysis BullosaBiological: EB-101Jean Yuh TangAbeona Therapeutics, IncNot yet recruiting6 YearsN/AAll15Phase 3NULL
3NCT03183934
(ClinicalTrials.gov)
July 20178/6/2017A Follow-up Study to Evaluate the Efficacy and Safety of ALLO-ASC-DFU in ALLO-ASC-EB-101 Clinical TrialA Follow-up Study to Evaluate the Efficacy and Safety for the Patients With ALLO-ASC-DFU Treatment in Phase 1/2 Clinical Trial of ALLO-ASC-EB-101Dystrophic Epidermolysis BullosaBiological: ALLO-ASC-DFUAnterogen Co., Ltd.NULLNot yet recruiting2 Years60 YearsAll5Phase 1;Phase 2Korea, Republic of